CTRI/2018/03/012308已完成未知
A single blinded (Investigator blinded), randomized study to evaluate and compare the efficacy of the hair leave-on product with a comparator product for scalp hair growth and density - NI
ITC Life Sciences Technology Centre0 个研究点目标入组 168 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Subjects to be 21 to 55 year old male and female generally in good health.
- •2)Female subjects falling under grade 2, 3 and grade 4 of hair loss severity grade evaluated as per standard Photo numeric 6 point scale.
- •3)Male subjects falling under grade 2, 3 and grade 4 of hair loss severity grade evaluated as per Norwood scale.
- •4)Subject having hair density 100-200 /cm2 will be included in the study.
- •5)Hair falls by comb test to be more than 15 hairs.
- •6)Subjects who give their consent to the study after thorough explanation and who personally signed and dated the informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
- •7)Willing to maintain the same hairstyle, hair length and hair color throughout the study.
- •8)Willingness to have a dot tattoo placed in the target area of the scalp during the study.
- •9)Willingness to maintain the habits and products during the study.
- •10)Able to comply with the study requirements for 6 consecutive months.
- •11)Subjects willing to refrain from other AGA/Female pattern hair loss treatments during the entire study duration.
- •12)Have no clinically significant disease or abnormal laboratory results taken at the screening visit.
- •13)Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, finasteride or dutasteride during the course of this study.
- •14)Subjects who are not on crash dieting
排除标准
- •1)Subjects who are undergoing hair growth treatment 3 months before screening into the study.
- •2)Subjects who have scalp conditions such as folliculitis, seborrheoic psoriasis of scalp, seborrheoic dermatitis and lichen planopilaris at the time of screening.
- •3)Subjects who have alopecia areata of scalp hair and scarring alopecia due to any cause such as DLE, SLE and lichen planus.
- •4)Subjects who have undergone hair straightening using hot iron or chemicals within 3 months.
- •5)Subjects who have undergone treatments of cancer chemotherapy within 6 months before starting study or plan to undergo the same during study terms.
- •6)Subjects who have history of alcoholism and/ or psychiatric disorder including trichotillomania.
- •7)Subjects who have had hair transplantation treatment.
- •8)Subjects who take pharmaceutical products that may cause hirsutism (ex. phenytoin) and finesteride for androgenic alopecia.
- •9)A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
- •10)Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study.
- •11)Subjects who are on oral multivitamin tablets containing biotin, zinc, selenium and unwilling to stop the usage 1 month before enrollment into study and throughout the study duration.
- •12)Subjects with hypertension and thyroid as confirmed by history or blood screening.
- •13)Female subjects who have been pregnant in last 1 year or lactating or nursing as established by medical history or planning to become pregnant during the study period.
- •14)Female subjects with the complaint of post pregnancy hair fall.
- •15)Subjects who have undergone hair dyeing in last 1 month or plan to undergo the same during the study period.
- •16)Subjects who suffered with acute severe illness in past 3 months as established by the medical history.
- •17)Chronic illness which may influence the cutaneous state.
- •18)Subjects participating in other similar cosmetic or therapeutic trial.
- •19)Any underlying uncontrolled medical illness including diabetes mellitus, HIV, hepatitis, anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
研究者
相似试验
进行中（未招募）
1 期
A proof-of-mechanism study to demonstrate the anti-inflammatory effect of fevipiprant in moderate to severe asthma patients with high sputum and blood eosinophilsAsthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-004381-33-ESovartis Farmacéutica, S.A58
进行中（未招募）
1 期
A proof-of-mechanism study to demonstrate the anti-inflammatory effect of fevipiprant in moderate to severe asthma patients with high sputum and blood eosinophilsAsthmaEUCTR2018-004381-33-GBovartis Pharma AG58
进行中（未招募）
1 期
A proof-of-mechanism study to demonstrate the anti-inflammatory effect of fevipiprant in moderate to severe asthma patients with high sputum and blood eosinophilsAsthmaEUCTR2018-004381-33-DEovartis Pharma AG58
进行中（未招募）
1 期
A proof-of-mechanism study to demonstrate the anti-inflammatory effect of fevipiprant in moderate to severe asthma patients with high sputum and blood eosinophilsAsthmaEUCTR2018-004381-33-BEovartis Pharma AG58
进行中（未招募）
1 期
A proof-of-mechanism study to demonstrate the anti-inflammatory effect of fevipiprant in moderate to severe asthma patients with high sputum and blood eosinophilsAsthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-004381-33-FRovartis Pharma AG58